1 day 3 hours ago
BI-1910 is now the second of the company's anti-tumour necrosis factor receptor 2 programmes to enter clinical development
1 day 3 hours ago
The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15
2 days 4 hours ago
Nitisinone capsules are indicated for patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine
2 days 4 hours ago
Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services
3 days 4 hours ago
The neurological disease affects approximately 2.8 million people worldwide
3 days 4 hours ago
The inflammatory form of arthritis is estimated to affect nearly 38 million people worldwide
4 days 4 hours ago
The EMA's human medicines committee concluded that the benefits of Adakveo did not outweigh its risks
4 days 4 hours ago
The drug has already been approved for this indication in the EU, with regulatory reviews continuing elsewhere including in the US
1 week 1 day ago
Therapy has been developed for use among children and adolescents with growth hormone deficiency
1 week 1 day ago
Life Sciences Council meeting hosted by chancellor Jeremy Hunt has unfolded in Downing Street
1 week 2 days ago
The collaboration aims to develop novel preclinical models with a view to identifying new treatments
1 week 2 days ago
Tumour treatment among all phase 1a cohorts in were concluded with no safety concerns
1 week 3 days ago
Celadon will sell a minimum of £3m worth of the high-THC product over the next three years
1 week 3 days ago
Vital data supports early intervention in order to treat chronic obstructive pulmonary disease
1 week 4 days ago
Vital financing will allow the company to build a pipeline of novel therapies targeting serious conditions
1 week 4 days ago
Receptor antagonist AM1476 developed as an anti-fibrotic treatment for lung and skin disorders
1 week 5 days ago
Treatment involves early Alzheimer’s disease and will be potentially used across Great Britain
1 week 5 days ago
ACD856 is the leading candidate therapy on the company’s NeuroRestore platform
2 weeks 1 day ago
Treatment concerns up to 150,000 patients in England with chronic heart failure
2 weeks 1 day ago
Screening patients to assess their clopidogrel resistance status will allow for alternative treatments
Checked
2 hours 54 minutes ago
PharmaTimes - The latest news in healthcare and life sciences - News RSS
Subscribe to Pharma times RSS Feed feed